1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hyperinsulinemia - Drugs In Development, 2022, provides an overview of the Hyperinsulinemia (Metabolic Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. Insulin resistance is the primary cause of hyperinsulinemia. Symptoms include weight gain, feeling anxious, fatigue and frequently hungry. Risk factors include higher triglyceride levels, high uric acid, weight gain, type 2 diabetes and hypertension. Treatment includes Insulin secretion inhibiting agents, diet, exercise and other lifestyle changes.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Hyperinsulinemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hyperinsulinemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Hyperinsulinemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperinsulinemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 1 and 3 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Hyperinsulinemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperinsulinemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hyperinsulinemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hyperinsulinemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hyperinsulinemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hyperinsulinemia (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hyperinsulinemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hyperinsulinemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Hyperinsulinemia - Overview
- Hyperinsulinemia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Hyperinsulinemia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hyperinsulinemia - Companies Involved in Therapeutics Development
- AmideBio, LLC
- Crinetics Pharmaceuticals Inc
- Eiger BioPharmaceuticals Inc
- Hanmi Pharmaceuticals Co Ltd
- PegBio Co Ltd
- Rezolute Inc
- Seneb BioSciences Inc
- Xeris Biopharma Holdings Inc
- Zealand Pharma AS
- Hyperinsulinemia - Drug Profiles
- ABG-023 - Drug Profile
- Product Description
- Mechanism Of Action
- avexitide acetate - Drug Profile
- Product Description
- Mechanism Of Action
- CRN-04777 - Drug Profile
- Product Description
- Mechanism Of Action
- dasiglucagon - Drug Profile
- Product Description
- Mechanism Of Action
- exendin-(9-39) - Drug Profile
- Product Description
- Mechanism Of Action
- glucagon - Drug Profile
- Product Description
- Mechanism Of Action
- HM-15136 - Drug Profile
- Product Description
- Mechanism Of Action
- PB-722 - Drug Profile
- Product Description
- Mechanism Of Action
- RZ-358 - Drug Profile
- Product Description
- Mechanism Of Action
- SNB-2401 - Drug Profile
- Product Description
- Mechanism Of Action
- Hyperinsulinemia - Dormant Projects
- Hyperinsulinemia - Discontinued Products
- Hyperinsulinemia - Product Development Milestones
- Featured News & Press Releases
- Nov 28, 2022: Crinetics Pharmaceuticals provides update on CRN04777 Program
- Oct 06, 2022: Innovation passport granted for CRN04777 for the treatment of congenital hyperinsulinism
- Oct 04, 2022: AmideBio awarded SBIR phase IIb grant to support pre-clinical development of its long-acting stable glucagon analog for the treatment of hyperinsulinism
- Sep 19, 2022: Zealand Pharma presents data from phase 3 trial of dasiglucagon in congenital hyperinsulinism at the 60th Annual ESPE Meeting
- Sep 17, 2022: Rezolute announces presentation at the 60th Annual ESPE Meeting
- Jun 13, 2022: Eiger BioPharmaceuticals announces new data supporting broader potential of avexitide in patients with post-bariatric hypoglycemia and hyperinsulinemic hypoglycemia after gastrointestinal surgeries
- May 19, 2022: Zealand Pharma announces positive results from phase 3 trial of dasiglucagon in pediatric patients with congenital hyperinsulinism (CHI)
- May 01, 2022: Rezolute announces positive data from its phase 2b (RIZE) Study of RZ358 in patients with congenital hyperinsulinism
- Apr 26, 2022: Rezolute announces RZ358 Phase 2b (RIZE Study) topline data to be unveiled at Pediatric Endocrine Society 2022 Annual Meeting
- Mar 30, 2022: Crinetics Pharmaceuticals reports positive top-line results from CRN04777 phase 1 study multiple-ascending dose cohorts
- Sep 22, 2021: Rezolute presents results from two-week natural history study in congenital hyperinsulinism patients on standard of care therapies at ESPE 2021
- Sep 15, 2021: Crinetics Pharmaceuticals’ oral SST5 agonist CRN04777 demonstrated pharmacologic proof-of-concept with strong dose-dependent suppression of insulin secretion in phase 1 single ascending dose study
- Sep 09, 2021: Rezolute announces initiation of dosing in the second cohort of its phase 2b trial of RZ358 for congenital hyperinsulinism
- Feb 03, 2021: Crinetics Pharmaceuticals advances CRN04777 for congenital hyperinsulinism into phase 1 study
- Jan 21, 2021: Hanmi Pharmaceutical’s innovative new drug HM15136 receives FDA phase 2 clinical trial approval
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Hyperinsulinemia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Hyperinsulinemia - Pipeline by AmideBio, LLC, 2022
- Hyperinsulinemia - Pipeline by Crinetics Pharmaceuticals Inc, 2022
- Hyperinsulinemia - Pipeline by Eiger BioPharmaceuticals Inc, 2022
- Hyperinsulinemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
- Hyperinsulinemia - Pipeline by PegBio Co Ltd, 2022
- Hyperinsulinemia - Pipeline by Rezolute Inc, 2022
- Hyperinsulinemia - Pipeline by Seneb BioSciences Inc, 2022
- Hyperinsulinemia - Pipeline by Xeris Biopharma Holdings Inc, 2022
- Hyperinsulinemia - Pipeline by Zealand Pharma AS, 2022
- Hyperinsulinemia - Dormant Projects, 2022
- Hyperinsulinemia - Discontinued Products, 2022
- Number of Products under Development for Hyperinsulinemia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AmideBio, LLC
- Crinetics Pharmaceuticals Inc
- Eiger BioPharmaceuticals Inc
- Hanmi Pharmaceuticals Co Ltd
- PegBio Co Ltd
- Rezolute Inc
- Seneb BioSciences Inc
- Xeris Biopharma Holdings Inc
- Zealand Pharma AS
